FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens ...

Incyte INCY announced that the FDA has approved the label expansion of Opzelura (ruxolitinib) cream 1.5%. Opzelura, a topical ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

Q: For almost two months now, I've had bumps on the back, sides and crown of my head. They itch all the time — and even more ...

The "Topical Drugs Packaging Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has ...

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough ...

If you or someone you love has eczema, you know treating it can be frustrating. It takes a lot of trial and error to f ...

Doctors have shared their top tips for travelling with eczema, offering some wise words for people who find heading to ...

Adults who suffer from the common disorder are significantly more likely to express suicidal thoughts, concerning new ...